Status:
COMPLETED
Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Conditions:
Advanced Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5, 2007 and July 30, 2008 were enrolled from 10 centers. The leader units are Shanghai Chest Hospital...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed, previously untreated stage IIIB or IV NSCLC
- age of 18-75 years
- at least one measurable lesion (RECIST)
- patients evaluated as SD or above after 1 cycle (21 days) of TC chemotherapy .
- adequate hematologic, cardiac, renal, and hepatic function
- ECOG PS 0-2
Exclusion
- symptomatic brain metastases
- bone metastases with complications
- major organ dysfunction
- bleeding diathesis or coagulopathy
- pregnant or lactating woman
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT00708812
Start Date
July 1 2007
End Date
December 1 2009
Last Update
July 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200039